Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81ba2c4156354c844d4a8883be561f00 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 |
filingDate |
1992-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d52d7ee900fd110eb8ac06396ec1b7d0 |
publicationDate |
1994-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-0590060-A1 |
titleOfInvention |
ORAL-AVAILABLE THERAPEUTIC PROTEINS AND PRODUCTION METHOD. |
abstract |
A therapeutic protein is administered orally by combining the therapeutic protein with a stabilizing agent in an aqueous solution. The solution is coated on a nonpareille and microencapsulated using an enteric coating composition emulsifiable in water. The microcapsules are administered orally. The coating protects the protein as it passes through the stomach. Once in the small intestine, the basic pH of the intestinal juices dissolves the coating, thus releasing the protein. The stabilizing agent protects the therapeutic protein during the encapsulation process and inhibits the proteolytic enzymes in the small intestine, thereby allowing the therapeutic protein to reach lymphoid tissue in the small intestine. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106460050-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0603992-B2 |
priorityDate |
1991-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |